Botulinum toxin B increases mouth opening in patients with spastic trismus

No abstract is available for this paper.

• Publication year

  2009

• Venue

  European Journal of Neurology

• Publication date

  2009-12-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1111/j.1468-1331.2009.02723.xPMID 19566902
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• The aetiology and pathogenesis of trismus.

  2009cited by this paper
• Clinical use of non-a botulinum toxins: botulinum toxin type B

  2006cited by this paper
• SV2 Is the Protein Receptor for Botulinum Neurotoxin A

  2006cited by this paper
• Secondary non‐response due to antibody formation in a child after three injections of botulinum toxin B into the salivary glands

  2006cited by this paper
• Management of spasticity in adults: practical application of botulinum toxin

  2006cited by this paper
• Severe trismus as a complication of cerebrovascular accident: a case report.

  2005influential reference
• Botulinum toxin B treatment in children with spastic movement disorders: a pilot study.

  2004cited by this paper
• Clinical impact of antibody formation to botulinum toxin A in children

  2004cited by this paper
• Trismus in head and neck oncology: a systematic review.

  2004cited by this paper
• Stroke-Induced Trismus in a Pediatric Patient: Long-Term Resolution with Botulinum Toxin A

  2003influential reference
• Botulinum neurotoxin serotypes A and B preparations have different safety margins in preclinical models of muscle weakening efficacy and systemic safety.

  2002cited by this paper
• Botulinum neurotoxin serotypes A and B preparations have different safety margins in preclinical models of muscle weakening efficacy and systemic safety.

  2002cited by this paper
• Treatment of Temporomandibular Disorders with Botulinum Toxin

  2002cited by this paper
• Autonomic Side Effects of Botulinum Toxin Type B Treatment of Cervical Dystonia and Hyperhidrosis

  2002cited by this paper
• Recurrent trismus and stridor in an ALS patient: successful treatment with botulinum toxin.

  2002cited by this paper
• Treatment of sialorrhoea with ultrasound guided botulinum toxin type A injection in patients with neurological disorders

  2001cited by this paper
• Botulinum toxin A as treatment for drooling saliva in PD

  2000cited by this paper
• Management of spasticity associated pain with botulinum toxin A.

  2000cited by this paper
• Valproate-induced hyperammonemic encephalopathy in the presence of topiramate

  2000cited by this paper
• Treating severe bruxism with botulinum toxin.

  2000influential reference
• Hemimasticatory spasm associated with localized scleroderma and facial hemiatrophy.

  2000cited by this paper
• Safety and efficacy of NeuroBloc (botulinum toxin type B) in type A-responsive cervical dystonia.

  1999cited by this paper
• Functional repair of motor endplates after botulinum neurotoxin type A poisoning: biphasic switch of synaptic activity between nerve sprouts and their parent terminals.

  1999cited by this paper
• A comparison of the spread of three formulations of botulinum neurotoxin A as determined by effects on muscle function

  1998cited by this paper
• Botulinum toxin type B: A double-blind, placebo-controlled, safety and efficacy study in cervical dystonia

  1997cited by this paper
• Trismus: causes, differential diagnosis, and treatment.

  1997cited by this paper
• Dosing, administration, and a treatment algorithm for use of botulinum toxin A for adult‐onset spasticity

  1997cited by this paper
• Clinical trials of botulinum toxin in the treatment of spasticity

  1997cited by this paper
• Masseter Muscle Rigidity Associated with Glycine sup 1306 ‐to‐ Alanine Mutation in the Adult Muscle Sodium Channel alpha‐Subunit Gene

  1995influential reference
• Masseter Muscle Rigidity Associated with Glycine1306-to- Alanine Mutation in the Adult Muscle Sodium Channel α-Subunit Gene

  1995cited by this paper
• Botulinum toxin a is effective in treating trismus associated with postradiation myokymia and muscle spasm

  1995cited by this paper
• Botulinum toxin A for trismus in cephalic tetanus.

  1994cited by this paper
• Mobilization regimens for the prevention of jaw hypomobility in the radiated patient: a comparison of three techniques.

  1993cited by this paper
• Botulinum neurotoxin A selectively cleaves the synaptic protein SNAP-25

  1993cited by this paper
• Tetanus and botulinum-B neurotoxins block neurotransmitter release by proteolytic cleavage of synaptobrevin

  1992cited by this paper
• Quantifying the spread of botulinum toxin through muscle fascia

  1991cited by this paper
• Botulinum A toxin for cranial‐cervical dystonia

  1987cited by this paper
• REVIEW The aetiology and pathogenesis of trismus

  1986cited by this paper

• Botulinum Toxin A in Poststroke Oromandibular Dystonia: Case Reports

  2026cites this paper
• Unilateral spastic trismus in brain stem stroke: A hindrance to oral care, mastication, and speech

  2025cites this paper
• Management of trismus after radiation therapy.

  2025cites this paper
• Tongue crushing Trismus following Brainstem Stroke

  2025cites this paper
• Effect of Botulinum Toxin Injection into the Masseter Muscle in Patients with Bruxism: A single-arm, Institutional-Based Prospective Clinical Study

  2025cites this paper
• Exploring Trismus Management in Australia: A Mixed Methods Evaluation of Surveys and Interviews With Health Professionals

  2024cites this paper
• Management of MACROGLOSSIA: Case Series and Suggested Algorithm.

  2022cites this paper
• Botulinum in selected neurological disorders - review

  2021cites this paper
• Exploring the role of botulinum toxin in critical care

  2021cites this paper
• Influence of Intramasseteric Injection of Botulinum Toxin Type A on the Ipsilateral Submandibular Salivary Gland of Albino Rats

  2020cites this paper
• Out of the spasticity box: Off-label uses of botulinum toxin in children

  2020cites this paper
• Botulinum toxin therapy improves masseter spasticity in Amyotrophic Lateral Sclerosis.

  2020cites this paper
• Botulinum Toxin A for Spastic Trismus Due to Brain Stem Encephalitis in a Pediatric Intensive Care Setting: A Unique Case Report

  2018cites this paper
• EFFECT OF INTRA-MASSETERIC BOTULINUM NEUROTOXIN INJECTION ON RAT PAROTID GLAND: HISTOMORPHOMETRIC, HISTOCHEMICAL AND IMMUNOHISTOCHEMICAL STUDY

  2018cites this paper
• Botulinum Toxin Treatment in Clinical Medicine: A Disease-Oriented Approach

  2018cites this paper
• Therapeutic uses and efficacy of botulinum toxin in orofacial medicine

  2018cites this paper
• Botulinum Toxin Treatment in Cerebrovascular Disease

  2018cites this paper
• Goal setting approaches and principles used in rehabilitation for people with acquired brain injury: A systematic scoping review

  2015cites this paper
• Memantine improves goal attainment and reduces caregiver burden in Parkinson's disease with dementia

  2013cites this paper
• Use of Rimabotulinum Toxin for Focal Hypertonicity Management in Children with Cerebral Palsy with Nonresponse to Onabotulinum Toxin

  2013cites this paper
• Trismus as the first symptom of amyotrophic lateral sclerosis

  2012cites this paper
• Severe Spastic Trismus without Generalized Spasticity after Unilateral Brain Stem Stroke

  2012cites this paper
• [Botulinum toxin in the treatment of adult spasticity. An interdisciplinary German 10-point consensus 2010].

  2011cites this paper
• Trismus—An important issue in pain and palliative care

  2010cites this paper
• Botulinum-Neurotoxin in der Behandlung der Spastizität im Erwachsenenalter

  2010cites this paper
• Botulinum Toxin and Dentistry

  2009cites this paper